安进

Amgen's 15min Chart Indicates Overbought RSI and Narrowing Bollinger Bands

Amgen: Argus Research raises PT to $400 from $360, maintains Buy rating.

Amgen: Guggenheim Raises PT to $347, Maintains Neutral Rating

Amgen's 15min chart signals Bollinger Bands Narrowing and KDJ Death Cross.

Amgen

Amgen's Earnings Beat Expectations Despite FDA Request to Pull Tavneos from Market

Catalyst<ul> <li>Small, Medium, and Large order inflows indicate positive fund flow activity for AMGN.</li></ul>Risk<ul> <li>Technical signals show bearish dominance with four negative indicators and no bullish ones in recent periods.</li> <li>Analyst ratings show inconsistency with only two Buy or Strong Buy ratings among six analysts, while four maintain Neutral ratings.</li></ul>

Key Factors

Amgen reported Q4 2025 revenue of $9.9 billion, exceeding the $9.46 billion consensus estimate, with adjusted EPS of $5.29 above the $4.73 forecast. The FDA requested the withdrawal of Amgen's Tavneos due to liver health concerns, though analysts expect limited impact on revenue or stock price. Amgen raised full-year 2026 revenue guidance to $37–38.4 billion and increased its EPS outlook to $21.60–$23.00, driving an 8.4% after-hours stock surge. Multiple analysts, including RBC, TD Cowen, and Leerink, raised Amgen's price targets following strong Q4 results and confidence in its obesity drug pipeline and key products.

AMGN News